The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
Official Title: An Open-label, Multi-center Phase IIIb Study of Durvalumab and Tremelimumab as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Study ID: NCT05557838
Brief Summary: This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Beijing, , China
Research Site, Beijing, , China
Research Site, Beijing, , China
Research Site, Beijing, , China
Research Site, Changsha, , China
Research Site, Changsha, , China
Research Site, Chengdu, , China
Research Site, Fuzhou, , China
Research Site, Guangzhou, , China
Research Site, Guangzhou, , China
Research Site, Guangzhou, , China
Research Site, Guangzhou, , China
Research Site, Hangzhou, , China
Research Site, Harbin, , China
Research Site, Ji Nan, , China
Research Site, Nanjing, , China
Research Site, Nanjing, , China
Research Site, Nanjing, , China
Research Site, Ningbo, , China
Research Site, Shanghai, , China
Research Site, Shanghai, , China
Research Site, Shenyang, , China
Research Site, Tianjin, , China
Research Site, Tianjin, , China
Research Site, Tianjin, , China
Research Site, Wenzhou, , China
Research Site, Wuhan, , China
Research Site, Wuhan, , China
Research Site, Xi'an, , China
Research Site, Zhangjiagang, , China
Research Site, Zhengzhou, , China
Research Site, Zhengzhou, , China